Craig-Hallum starts Cardiff at Buy with onvansertib ‘nearing promised land’

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Cardiff Oncology with a Buy rating and $8 price target, citing the belief that onvansertib’s clinical experience in second-line KRASmutant mCRC “clearly demonstrates its efficacy in bev naive patients” and supports moving to the first-line setting. While acknowledging that onvansertib has “taken a long journey to reach this point,” the firm believes the “circuitous route was ultimately advantageous” and contends that the program is now well-positioned with a clear path toward approval in the “expansive patient population” of first-line RAS-mutated metastatic colorectal cancer.